Effects of omega-3 supplementation on interleukin and neurotrophin levels in an animal model of schizophrenia

• Autor(a) principal: Zugno, Alexandra Ioppi
• Data de Publicação: 2015
• Outros Autores: Canever, Lara, Chipindo, Helder, L., Mastella, Gustavo Antunes, Heylmann, Alexandra S., Oliveira, Mariana B., Steckert, Amanda Valnier, Castro, Adalberto A., Dal Pizzol, Felipe, Quevedo, João Luciano de, Gama, Clarissa Severino
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/152814
• topic: Esquizofrenia; Ácidos graxos ômega-3; Ketamina; Omega-3; Ketamine; Schizophrenia; Neurotrophins; Interleukins

New studies suggest that polyunsaturated fatty acids, such as omega-3, may reduce the symptoms of schizophrenia. The present study evaluated the preventive effect of omega-3 on interleukines (IL) and neurotrophin brain-derived neurotrophic factor (BDNF) levels in the brains of young rats subjected to a model of schizophrenia. Treatment was performed over 21 days, starting on the 30th day of rat’s life. After 14 days of treatment with omega-3 or vehicle, a concomitant treatment with saline or ketamine (25 mg/kg) was started and maintained until the last day of the experiment. BDNF levels in the rat’s prefrontal cortex were decreased at 1 h and 24 h after the last administration of ketamine, whereas the group administered with ketamine and omega-3 showed a decrease in BDNF levels only after 24 h. In contrast, both interventions induced similar responses in levels of IL-1β and IL6. These findings suggest that the similarity of IL-1β and IL6 levels in our experimental groups is due to the mechanism of action of ketamine on the immune system. More studies have to be carried out to explain this pathology. In conclusion, according to previous studies and considering the current study, we could suggest a prophylactic role of omega-3 against the outcome of symptoms associated with schizophrenia.